{"title":"慢性髓性白血病(CML)难治性疾病的治疗——关注治疗CML的医生的意见","authors":"A. E. Eşkazan","doi":"10.17925/EOH.2017.13.01.15","DOIUrl":null,"url":null,"abstract":"A lthough the management of patients with chronic myeloid leukaemia in chronic phase (CML-CP), especially in the newlydiagnosed patient, is generally straightforward, it may vary in the salvage setting, since some of the currently approved tyrosine kinase inhibitors are not available in some countries. This commentary mainly focuses on a questionnaire and the subsequent paper, which were performed in order to understand the perspectives of the CML-treating physicians from different countries in the management of refractory CML-CP.","PeriodicalId":38554,"journal":{"name":"European Oncology and Haematology","volume":"19 1","pages":"15"},"PeriodicalIF":0.0000,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The Management of Chronic Myeloid Leukaemia (CML) Patients with Refractory Disease – Focusing on the Opinions of CML-treating Physicians\",\"authors\":\"A. E. Eşkazan\",\"doi\":\"10.17925/EOH.2017.13.01.15\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"A lthough the management of patients with chronic myeloid leukaemia in chronic phase (CML-CP), especially in the newlydiagnosed patient, is generally straightforward, it may vary in the salvage setting, since some of the currently approved tyrosine kinase inhibitors are not available in some countries. This commentary mainly focuses on a questionnaire and the subsequent paper, which were performed in order to understand the perspectives of the CML-treating physicians from different countries in the management of refractory CML-CP.\",\"PeriodicalId\":38554,\"journal\":{\"name\":\"European Oncology and Haematology\",\"volume\":\"19 1\",\"pages\":\"15\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2017-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Oncology and Haematology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.17925/EOH.2017.13.01.15\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Oncology and Haematology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17925/EOH.2017.13.01.15","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
The Management of Chronic Myeloid Leukaemia (CML) Patients with Refractory Disease – Focusing on the Opinions of CML-treating Physicians
A lthough the management of patients with chronic myeloid leukaemia in chronic phase (CML-CP), especially in the newlydiagnosed patient, is generally straightforward, it may vary in the salvage setting, since some of the currently approved tyrosine kinase inhibitors are not available in some countries. This commentary mainly focuses on a questionnaire and the subsequent paper, which were performed in order to understand the perspectives of the CML-treating physicians from different countries in the management of refractory CML-CP.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
